GlaxoSmithKline
π¬π§United Kingdom
- Country
- π¬π§United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
A Study in Healthy Volunteers to Evaluate the Application of Stable Isotope Approach to Reduce Number of Subjects Needed for PK Studies
Phase 1
Completed
- Conditions
- Metabolic, Cardiovascular
- Interventions
- Drug: Tab carvedilol 25 mgDrug: Powder carvedilol up to 2.5 mgDrug: Tab carvedilol 6.25 mg
- First Posted Date
- 2013-02-18
- Last Posted Date
- 2017-06-12
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 17
- Registration Number
- NCT01793870
- Locations
- π¬π§
GSK Investigational Site, Cambridge, United Kingdom
Healthcare Seeking Behaviour of Primary Caregivers for Acute Otitis Media (AOM) in Children Aged 6 Months to Less Than 30 Months in Panama
Completed
- Conditions
- Infections, Streptococcal
- Interventions
- Other: Data collection
- First Posted Date
- 2013-02-18
- Last Posted Date
- 2015-12-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1330
- Registration Number
- NCT01793857
- Locations
- π΅π¦
GSK Investigational Site, Pueblo Nuevo, Panama
Safety and Tolerability Study of GlaxoSmithKline (GSK)1557484A Vaccine in Adults at Occupational Risk for Influenza A (H5N1) Exposure
Phase 3
Completed
- Conditions
- InfluenzaInfluenza Vaccines
- Interventions
- Biological: Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia)
- First Posted Date
- 2013-02-11
- Last Posted Date
- 2020-06-23
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 50
- Registration Number
- NCT01788228
- Locations
- πΊπΈ
GSK Investigational Site, Madison, Wisconsin, United States
To Investigate the Safety, Pharmacodynamics and Effect on Allergic Reactivity of the Toll-like Receptor 7 (TLR7) Agonist GSK2245035 in Subjects With Respiratory Allergies
Phase 2
Completed
- Conditions
- Mild Asthma and Allergic Rhinitis
- Interventions
- Drug: Placebo
- First Posted Date
- 2013-02-11
- Last Posted Date
- 2014-10-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 42
- Registration Number
- NCT01788813
- Locations
- π¨π¦
GSK Investigational Site, Kingston, Ontario, Canada
Treatment Options in Human Epidermal Growth Factor Receptor 2 (HER2) Positive Metastatic Breast Cancer Patients
- First Posted Date
- 2013-02-04
- Last Posted Date
- 2015-08-10
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 1
- Registration Number
- NCT01782651
- Locations
- ππΊ
GSK Investigational Site, Debrecen, Hungary
A Dose Ranging Study to Evaluate the Safety and Efficacy of GSK2586184 in Patients With Chronic Plaque Psoriasis
Phase 2
Completed
- Conditions
- Psoriasis
- Interventions
- Drug: 400 mg GSK2586184Drug: 100 mg GSK2586184Drug: 200 mg GSK2586184Drug: Placebo
- First Posted Date
- 2013-02-04
- Last Posted Date
- 2017-08-03
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 68
- Registration Number
- NCT01782664
- Locations
- π¬π§
GSK Investigational Site, Salford, United Kingdom
Acceptability of Hepatitis B Vaccination in General Population
Completed
- Conditions
- Hepatitis B
- Interventions
- Other: Data collection
- First Posted Date
- 2013-02-04
- Last Posted Date
- 2013-02-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 2413
- Registration Number
- NCT01782794
Prospective Sexual Function Study for BPH Subjects
Phase 4
Completed
- Conditions
- Prostatic Hyperplasia
- Interventions
- Drug: Placebo
- First Posted Date
- 2013-01-28
- Last Posted Date
- 2018-08-20
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 489
- Registration Number
- NCT01777269
- Locations
- πͺπΈ
GSK Investigational Site, Vitoria- Gasteiz, Spain
A Study to Determine the Long Term Safety and Efficacy of Albiglutide in Combination With Oral Monotherapy Antihyperglycemic Medications in Japanese Patients With Type 2 Diabetes Mellitus
Phase 3
Completed
- Conditions
- Diabetes Mellitus
- Interventions
- Drug: SulfonylureaDrug: Glinide
- First Posted Date
- 2013-01-28
- Last Posted Date
- 2017-05-03
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 374
- Registration Number
- NCT01777282
- Locations
- π―π΅
GSK Investigational Site, Tokyo, Japan
A Study to Evaluate the Safety of GSK2398852 When Co-administered With GSK2315698 in Patients With Systemic Amyloidosis
- First Posted Date
- 2013-01-28
- Last Posted Date
- 2018-07-24
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 25
- Registration Number
- NCT01777243
- Locations
- π¬π§
GSK Investigational Site, London, United Kingdom
Β© Copyright 2025. All Rights Reserved by MedPath